PPM1H is a p27 phosphatase implicated in trastuzumab resistanceAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerIntegrative cancer epidemiology--the next generationThe transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progressionCD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissuesLymphatic Vessels, Inflammation, and Immunity in Skin CancerMesothelin-Targeted CARs: Driving T Cells to Solid TumorsPancreatic Cancer Metabolism: Breaking It Down to Build It Back UpHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerMYC, Metabolism, and CancerAdaptive Immune Resistance: How Cancer Protects from Immune AttackEvolutionary determinants of cancerClinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesUniverses collide: combining immunotherapy with targeted therapy for cancerWhat a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathwayBeyond DNA repair: DNA-PK function in cancerImproving the efficacy of chemoradiation with targeted agentsInvestigating metformin for cancer prevention and treatment: the end of the beginningTherapeutic insights from genomic studies of head and neck squamous cell carcinomasMisregulation of pre-mRNA alternative splicing in cancerThe BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer TherapeuticsTargeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancersThe emergence of lncRNAs in cancer biologyMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancermiRNA Deregulation in Cancer Cells and the Tumor MicroenvironmentExemestane for breast cancer prevention: a critical shift?Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode DependentThe ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung CancerFirst Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling PathwaySelective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive StateMutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitorsReactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Elucidating distinct roles for NF1 in melanomagenesisActivating HER2 mutations in HER2 gene amplification negative breast cancerA genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.Identification of targetable FGFR gene fusions in diverse cancers.
P1433
Q24322629-1FA3E774-BEAF-4E0F-B874-BA99DA96B608Q24563539-3902472D-F2A0-4E0A-ADC6-CCC402457C8EQ24594622-5C33AACE-28D4-4F41-8986-4A02FBB60054Q24632821-E6FC2D20-7E10-428C-B16B-4C6E21CEB130Q24633702-E16FC91C-CFD6-475A-8E47-E60A12F78F5DQ26778332-2E492E91-FE62-4BE8-8570-98885CBE55D0Q26778759-73913ECA-D0A8-4C51-9A21-D0F07707A0D9Q26780372-7E2ED247-7BD8-47F7-A8E1-669C8550E791Q26783551-0FD69DEA-CFB5-4300-8118-84C7C4F60916Q26783555-2DDF8630-A744-495D-9504-F5B41DEDD09CQ26798448-A40B2C37-585C-4FE5-974F-25B80A72BEAAQ26801710-18C6A1D9-42E8-4C2D-A470-440A68EF0C1AQ26823978-DE87A8A5-7D0D-4020-B984-8036D9A250CBQ26825316-1D612F44-8C7F-4E02-91E3-C88D610DD19AQ26825780-44510219-F9A1-4817-9B4A-A300611F2208Q26827232-E5C921D5-1E5F-4534-823E-B40663F2852AQ26850193-E4CC4818-3C0B-428D-8ABC-4E3AE0882D2FQ26863783-AE214E13-2FCB-4706-BF97-9D706109A376Q27006854-A4D889BC-3EC5-4E2B-9C0D-690CA353D3FEQ27007114-878F7BEE-EE2D-4BA3-BE9C-AF1EF57721B0Q27010154-E02102FE-8588-428E-9D86-EC8BC71AF5CCQ27022240-3DE30ABB-1393-4453-B990-F2BEE767C207Q27024237-B17B0E32-FF25-456C-BA1A-8387B088E6B2Q27024775-11C7CADA-9E2B-4497-A7CE-131B97B15C78Q27025496-6671DA0E-63E6-4416-AC29-A426DA05FD69Q27028211-28808F7E-5CE4-46A5-82BA-01EF15509AF9Q27345462-762B79F4-59EE-406C-B8FB-E1AE0F873DDAQ27681086-B8C08466-597C-47D5-86CA-5D555C8F7B95Q27682565-F3947927-6B7B-4F64-B9D1-66CF94065C08Q27698508-C6BB583C-1945-4E00-881C-35C4F3D7168BQ27703510-BD8C43FD-B6C8-4C0A-8213-7BB98D2FBDECQ27851720-7DB4E740-A2D0-4A42-8316-90638F31BA3DQ27851725-12AFC25C-A511-47C0-AC2D-C803FA69D3E5Q27851787-C564FDE0-AA91-4FA1-BA80-EBCA322BBC44Q27851843-E47CFDEF-8E48-45B3-8297-07FD32A1020BQ27851896-98213DDD-D627-4054-BF1A-EC68CA7F72E4Q27851952-77B16757-14AB-4BD2-8700-B05652072D0CQ27851987-37BF63E5-052D-42E8-85E5-D95DC60A0274Q27852017-9BE37D09-C52B-4206-A6F9-538F07EBFB40Q27852147-9DE84CBC-DE55-4964-9B3B-E14624D17989
P1433
description
czasopismo naukowe
@pl
publikation
@de
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
scientific journal
@en
vědecký časopis
@cs
wetenschappelijk tijdschrift
@nl
науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Cancer Discovery
@ast
Cancer Discovery
@de
Cancer Discovery
@en
Cancer Discovery
@es
Cancer Discovery
@fr
Cancer Discovery
@it
Cancer Discovery
@nl
type
label
Cancer Discovery
@ast
Cancer Discovery
@de
Cancer Discovery
@en
Cancer Discovery
@es
Cancer Discovery
@fr
Cancer Discovery
@it
Cancer Discovery
@nl
prefLabel
Cancer Discovery
@ast
Cancer Discovery
@de
Cancer Discovery
@en
Cancer Discovery
@es
Cancer Discovery
@fr
Cancer Discovery
@it
Cancer Discovery
@nl
P3181
P4616
P1055
P1058
P1156
21100212318
P1277
P1476
Cancer Discovery
@en
P236
P571
2011-01-01T00:00:00Z